CHENGDU EASTON BIO PHARMACEUTICALSCC

CHENGDU EASTON BIO PHARMACEUTICALS

64.30CNYD
+1.78+2.85%
At close at 09:23 GMT
CNY
No trades
See on Supercharts

688513 fundamentals

Key facts

Market capitalization‪11.04 B‬CNY
Founded2009
Employees (FY)‪1.52 K‬
CEOMing Xu Yuan
About

Chengdu Easton Bio Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of chemical raw materials and drug preparation. Its products include anti-tumor medicines such as Ubenimex capsules and ibandronate injections; cardiovascular medicines such as bisoprolol fumarate tablets; digestive medicines such as compound glycyrrhizin injections; anesthesia and analgesic products such as nalmefene hydrochloride injections and ibuprofen; and children’s medications. The company was founded by Ying Wang on June 1, 2009 and is headquartered in Chengdu, China.

Ownership
‪‪173.93 M‬‬
Closely held shares
‪‪96.80 M‬‬ (55.65%)
Free Float shares
‪‪77.14 M‬‬ (44.35%)
Closely held shares
‪‪96.80 M‬‬ (55.65%)
Free Float shares
‪‪77.14 M‬‬ (44.35%)
Capital structure
Market cap
‪‪11.04 B‬‬
Debt
‪‪173.98 M‬‬
Cash & equivalents
‪‪1.49 B‬‬
Enterprise value
‪‪9.72 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪11.04 B‬‬
Price to earning ratio (P/E)
54.39x
Price to sales ratio (P/S)
8.24x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
54.39x
Price to sales ratio (P/S)
8.24x
Valuation ratios
‪0.00‬
‪2.00‬
‪4.00‬
‪6.00‬
‪8.00‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪8.00‬
‪16.00‬
‪24.00‬
‪32.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪6.5%‬
‪11.5%‬
‪16.5%‬
‪21.5%‬
‪26.5%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪100.00 M‬‬
‪‪200.00 M‬‬
‪‪300.00 M‬‬
‪‪400.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪80.00 M‬‬
‪‪160.00 M‬‬
‪‪240.00 M‬‬
‪‪320.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪80.00 M‬‬
‪‪160.00 M‬‬
‪‪240.00 M‬‬
‪‪320.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Chemical Preparations
Application Programming Interface
Contract Manufacturing Organization/Contract Development and Manufacturing Organization
Technical Services and Transfer
Other
By country
Period: 2024
China
Overseas

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪100.00 M‬‬
‪‪200.00 M‬‬
‪‪300.00 M‬‬
‪‪400.00 M‬‬
Actual
Earnings
Next:Mar 31, 2026
2023
2024
2025
‪0.00‬
‪0.40‬
‪0.80‬
‪1.20‬
‪1.60‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
0.00%
Payout ratio (TTM)
Dividend yield TTM
0.69%
Last payment
0.43
Last ex-date
Jun 11, 2025
Last pay date
Jun 11, 2025
Dividend history
‪0.6%‬
‪0.9%‬
‪1.2%‬
‪1.5%‬
‪1.8%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.15‬
‪0.30‬
‪0.45‬
‪0.60‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−350.00 M‬‬
‪0.00‬
‪‪350.00 M‬‬
‪‪700.00 M‬‬
‪‪1.05 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪500.00 M‬‬
‪‪1.00 B‬‬
‪‪1.50 B‬‬
‪‪2.00 B‬‬
Assets
Liabilities